Recently Added |View More
News
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.
News
Prantesh Jain, MD, FACP, Assistant Professor of Oncology, Department of Medicine at Roswell Park Comprehensive Cancer Center, will share initial results of the study during the 2025 annual meeting of the American Association for Cancer ...
News
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025
Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.
News
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.
News
Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park
Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...
News
Encouraging results from a phase 1 clinical trial conducted at Roswell Park Comprehensive Cancer Center between 2019-2020 have laid the foundation for a phase 1/2a study for patients with metastatic or unresectable triple negative breast cancer (mTNBC)
News
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
News
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.
The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.
News
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED